Only 11% of drugs that enter clinical trials in humans are ultimately found safe and effective enough to receive regulatory approval.
Badly designed studies may lead to the efficacy of drugs being overestimated and money being wasted on trials that prove fruitless, according to a new study from McGill University in Canada.